Cargando…

The impact of antipsychotic adherence on acute care utilization

BACKGROUND: Non-adherence to psychotropic medications is common in schizophrenia and bipolar disorders (BDs) leading to adverse outcomes. We examined patterns of antipsychotic use in schizophrenia and BD and their impact on subsequent acute care utilization. METHODS: We used electronic health record...

Descripción completa

Detalles Bibliográficos
Autores principales: Perkins, Anthony J., Khandker, Rezaul, Overley, Ashley, Solid, Craig A., Chekani, Farid, Roberts, Anna, Dexter, Paul, Boustani, Malaz A., Hulvershorn, Leslie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9875466/
https://www.ncbi.nlm.nih.gov/pubmed/36694142
http://dx.doi.org/10.1186/s12888-023-04558-6
_version_ 1784877966874902528
author Perkins, Anthony J.
Khandker, Rezaul
Overley, Ashley
Solid, Craig A.
Chekani, Farid
Roberts, Anna
Dexter, Paul
Boustani, Malaz A.
Hulvershorn, Leslie
author_facet Perkins, Anthony J.
Khandker, Rezaul
Overley, Ashley
Solid, Craig A.
Chekani, Farid
Roberts, Anna
Dexter, Paul
Boustani, Malaz A.
Hulvershorn, Leslie
author_sort Perkins, Anthony J.
collection PubMed
description BACKGROUND: Non-adherence to psychotropic medications is common in schizophrenia and bipolar disorders (BDs) leading to adverse outcomes. We examined patterns of antipsychotic use in schizophrenia and BD and their impact on subsequent acute care utilization. METHODS: We used electronic health record (EHR) data of 577 individuals with schizophrenia, 795 with BD, and 618 using antipsychotics without a diagnosis of either illness at two large health systems. We structured three antipsychotics exposure variables: the proportion of days covered (PDC) to measure adherence; medication switch as a new antipsychotic prescription that was different than the initial antipsychotic; and medication stoppage as the lack of an antipsychotic order or fill data in the EHR after the date when the previous supply would have been depleted. Outcome measures included the frequency of inpatient and emergency department (ED) visits up to 12 months after treatment initiation. RESULTS: Approximately half of the study population were adherent to their antipsychotic medication (a PDC ≥ 0.80): 53.6% of those with schizophrenia, 52.4% of those with BD, and 50.3% of those without either diagnosis. Among schizophrenia patients, 22.5% switched medications and 15.1% stopped therapy. Switching and stopping occurred in 15.8% and 15.1% of BD patients and 7.4% and 20.1% of those without either diagnosis, respectively. Across the three cohorts, non-adherence, switching, and stopping therapy were all associated with increased acute care utilization, even after adjusting for baseline demographics, health insurance, past acute care utilization, and comorbidity. CONCLUSION: Non-continuous antipsychotic use is common and associated with high acute care utilization. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12888-023-04558-6.
format Online
Article
Text
id pubmed-9875466
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-98754662023-01-26 The impact of antipsychotic adherence on acute care utilization Perkins, Anthony J. Khandker, Rezaul Overley, Ashley Solid, Craig A. Chekani, Farid Roberts, Anna Dexter, Paul Boustani, Malaz A. Hulvershorn, Leslie BMC Psychiatry Research BACKGROUND: Non-adherence to psychotropic medications is common in schizophrenia and bipolar disorders (BDs) leading to adverse outcomes. We examined patterns of antipsychotic use in schizophrenia and BD and their impact on subsequent acute care utilization. METHODS: We used electronic health record (EHR) data of 577 individuals with schizophrenia, 795 with BD, and 618 using antipsychotics without a diagnosis of either illness at two large health systems. We structured three antipsychotics exposure variables: the proportion of days covered (PDC) to measure adherence; medication switch as a new antipsychotic prescription that was different than the initial antipsychotic; and medication stoppage as the lack of an antipsychotic order or fill data in the EHR after the date when the previous supply would have been depleted. Outcome measures included the frequency of inpatient and emergency department (ED) visits up to 12 months after treatment initiation. RESULTS: Approximately half of the study population were adherent to their antipsychotic medication (a PDC ≥ 0.80): 53.6% of those with schizophrenia, 52.4% of those with BD, and 50.3% of those without either diagnosis. Among schizophrenia patients, 22.5% switched medications and 15.1% stopped therapy. Switching and stopping occurred in 15.8% and 15.1% of BD patients and 7.4% and 20.1% of those without either diagnosis, respectively. Across the three cohorts, non-adherence, switching, and stopping therapy were all associated with increased acute care utilization, even after adjusting for baseline demographics, health insurance, past acute care utilization, and comorbidity. CONCLUSION: Non-continuous antipsychotic use is common and associated with high acute care utilization. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12888-023-04558-6. BioMed Central 2023-01-24 /pmc/articles/PMC9875466/ /pubmed/36694142 http://dx.doi.org/10.1186/s12888-023-04558-6 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Perkins, Anthony J.
Khandker, Rezaul
Overley, Ashley
Solid, Craig A.
Chekani, Farid
Roberts, Anna
Dexter, Paul
Boustani, Malaz A.
Hulvershorn, Leslie
The impact of antipsychotic adherence on acute care utilization
title The impact of antipsychotic adherence on acute care utilization
title_full The impact of antipsychotic adherence on acute care utilization
title_fullStr The impact of antipsychotic adherence on acute care utilization
title_full_unstemmed The impact of antipsychotic adherence on acute care utilization
title_short The impact of antipsychotic adherence on acute care utilization
title_sort impact of antipsychotic adherence on acute care utilization
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9875466/
https://www.ncbi.nlm.nih.gov/pubmed/36694142
http://dx.doi.org/10.1186/s12888-023-04558-6
work_keys_str_mv AT perkinsanthonyj theimpactofantipsychoticadherenceonacutecareutilization
AT khandkerrezaul theimpactofantipsychoticadherenceonacutecareutilization
AT overleyashley theimpactofantipsychoticadherenceonacutecareutilization
AT solidcraiga theimpactofantipsychoticadherenceonacutecareutilization
AT chekanifarid theimpactofantipsychoticadherenceonacutecareutilization
AT robertsanna theimpactofantipsychoticadherenceonacutecareutilization
AT dexterpaul theimpactofantipsychoticadherenceonacutecareutilization
AT boustanimalaza theimpactofantipsychoticadherenceonacutecareutilization
AT hulvershornleslie theimpactofantipsychoticadherenceonacutecareutilization
AT perkinsanthonyj impactofantipsychoticadherenceonacutecareutilization
AT khandkerrezaul impactofantipsychoticadherenceonacutecareutilization
AT overleyashley impactofantipsychoticadherenceonacutecareutilization
AT solidcraiga impactofantipsychoticadherenceonacutecareutilization
AT chekanifarid impactofantipsychoticadherenceonacutecareutilization
AT robertsanna impactofantipsychoticadherenceonacutecareutilization
AT dexterpaul impactofantipsychoticadherenceonacutecareutilization
AT boustanimalaza impactofantipsychoticadherenceonacutecareutilization
AT hulvershornleslie impactofantipsychoticadherenceonacutecareutilization